Biochemical characterization of human vascular endothelial cell-monocyte antigens defined by monoclonal antibodies

Although the clinical relevance of endothelial cell-monocyte (E-M) antigens has been demonstrated in organ graft transplantation, very limited data exist describing the nature of these antigens. The current study presents biochemical characterization of three different surface antigens of endothelial cells and monocytes that are defined by murine monoclonals produced against gamma-interferon-induced human umbilical vein endothelial cells. The antigens gp150, gp48, and gp24 have molecular weights of 150,000, 48,000, and 24,000, respectively, under reducing conditions. The antibody binding sites of gp150 and gp48 are destroyed by pronase and chymotrypsin, indicating that the molecules are at least partly protein in nature. The inability to label the gp48 molecule with 125I using lactoperoxidase suggests that there is little protein structure exposed to the cell surface or that the molecule lacks sufficient cell surface tyrosine residues to enable detection. Immunoprecipitation of the gp24 molecule under nonreducing conditions shows that a molecule with a higher molecular weight ranging from 40,000-70,000 is detected. Although it is possible that this higher-molecular-weight species is a multimer of the 24,000 Mr species, it is also possible that there is another molecule(s) bound to the 24,000 Mr molecule. All three E-M antigens have some carbohydrate nature as evidenced by lectin-binding studies. The possible relevance of these antigens in the rejection of transplanted organ grafts is discussed.     

Clinical significance of in situ detection of T lymphocyte subsets and monocyte/macrophage lineages in heart allografts

Seventy fresh frozen biopsies of 22 human heart allografts were stained with mouse antihuman monoclonal antibodies (OKT-4, OKT-8, and OKM-1) using the immunoperoxidase method. The numbers of infiltrating cell phenotypes were correlated with patients' clinical status and histopathological diagnoses of the biopsies. At the clinically stable stage the number of OKT-4-positive cells (T-4 cells, helper/inducer), OKT-8-positive cells (T-8 cells, suppressor/cytotoxic), OKM-1-positive cells (M-1 cells, monocyte/macrophage) and T4/T8 ratio were lowest. During the early stage of rejection T-4 cells increased to the highest values. T-8 cells also increased significantly and T4/T8 ratio increased to the peak level as well. During the later stage of rejection, T-8 and M-1 cells increased to the highest values and T-4 cells and T4/T8 ratio decreased. After the treatment of rejection T-4 cells continued to decrease and T-8 cells and M-1 cells decreased to intermediate levels, but T4/T8 ratio still remained level. The numbers of T-4 cells, T-8, cells and M-1 cells were closely associated with the histopathologic severity of rejection. These results were also correlated with the allografts' prognoses. Interestingly, high T4/8 ratios with high number of T-4 cells in biopsies during the quiescent period were often followed by rejection episodes within 7 days, even though the pathological diagnoses were mild rejection. Another important finding was that after the treatment of rejection, persistent M-1 cells and low T4/T8 ratios in situ were frequently accompanied by recurrent rejections. Thus, monitoring of infiltrating cell phenotypes may be beneficial in the management of clinical cardiac transplantations.     

Acute monoblastic leukemia in two infants: Clinical,histochemical, and immunologic investigations

Two infant girls developed acute non-lymphocytic leukemia. One had previously had cutaneous nodules diagnosed as a malignancy of the reticulo-endothelial system. The purpose of this work was to characterize the malignant cells and to summarize the response to treatment. Malignant cells from both patients resembled monoblasts morphologically, and the esterase staining pattern suggested monocytic differentiation. Leukemic cells from one patient were capable of phagocytosis. Immunoglobulin G was detected on the surface membranes of the malignant cells of both patients. Blast cells from both patients were examined repeatedly for the presence of leukemia-associated antigens, using various antisera to human leukemia cells, and the reactivity pattern was similar to that of blasts from other patients with acute myelomonocytic leukemia. The evolution of the disease and rapid clinical course in both infants was consistent with the diagnosis of acute monoblastic leukemia. Because of its poor prognosis, this disorder should be distinguished from the more common varieties of childhood acute leukemia.     

Acetylcholinesterase changes in the central nervous system of mice during the development of morphine tolerance addiction and withdrawal

The distribution of acetylcholinesterase in the brain is studied during the development of morphine tolerance and through a period of withdrawal to elucidate the possible role of this enzyme in producing physical dependence in mice. Tolerance and physical dependence are produced in male albino mice by giving morphine sulphate subcutaneously at eight hourly intervals, in an increasing dose of 10 mg/kg body weight every 24 hours, for 15 days. The animals are considered addicted, when they received an otherwise lethal dose, 150 mg/kg three times a day. The enzyme shows a marked elevation in the overall distribution during the development of physical dependence. The habenular complex, nuclei anterioventralis and medialis thalami, nucleus caudatus putamen, amygdaloideus lateralis, septal nuclei, nucleus nervi hypoglossi, nucleus reticularis lateralis, tuberculum olfactorium, nucleus tractus diagonalis brocae, stratum pyramidale hippocampi, nucleus paraventricularis thalami, nucleus dorsalis nervi vagi, nucleus tractus spinalis nervi trigemini and nucleus reticularis thalami show an increase in the enzyme activity. This enhancement is not linear with the increase in dosage. Withdrawal is characterised by a sudden fall in the activity of acetylcholinesterase in the above mentioned areas of brain.     

Relationship of B cell alloantibodies to renal allograft survival.

To define the relationship of donor-specific B lymphocyte alloantibodies to renal allograft survival, longitudinal serum samples obtained pre- and post-transplantation were examined for antibodies cytotoxic to donor B lymphocytes. Ten of 17 renal allograft recipients had antibodies to donor B lymphocytes but not T lymphocytes either pre- and/or post-transplantation. Three patients underwent successful transplants despite preformed B cell antibodies; however, seven who developed B cell antibodies only after transplantation are either undergoing chronic rejection (4) or have had severe rejection crisis (3). Seven patients with no B cell antibodies have functioning grafts. In all cases, B cell antibodies were detected before biochemical and clinical evidence of rejection. Similar findings were noted when sera of 38 renal transplant recipients were examined for B cell antibodies cytotoxic to an unrelated panel of B lymphocytes. These results demonstrate that the development of B cell alloantibodies after transplantation is often associated with rejection and that successful renal transplantation can be performed across a positive B cell crossmatch.     

Survival of long nerve allografts following donor antigen pretreatment: a pilot study

In this study, the authors evaluated whether the pretransplant portal venous administration of UV-B irradiated donor alloantigen would induce tolerance to long peripheral nerve allografts in a swine model. They completed nerve allograft transplantation between four swine of separate lineages. Regeneration across the nerve allografts was followed for 10 months postoperatively. Sequential IN VITRO assays demonstrated the successful and prolonged suppression of the recipient immune response to donor antigen following antigen inoculation. Histomorphometric analysis demonstrated successful regeneration across the long nerve allografts in the pretreated recipients, but not across allografts in unimmunosuppressed recipients. A single pretransplant antigen delivery protocol has the potential to replace chronic medicinal immunosuppressant therapy and its associated morbidities. Furthermore, tolerance to long nerve allografts has immediate applicability to clinical requirements for bridging multiple, complex, long nerve gaps.